Literature DB >> 15228234

Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia.

Robert E Brown1, Bruce Bostrom, Ping L Zhang.   

Abstract

"Morphoproteomics" is defined as the identification by immunohistochemistry of the molecular circuitry of various proteins in a tumor by noting their state of activation (translocation and phosphorylation) and correlative expressions. This approach can uncover potential targets, amenable to therapeutic interventions, that are specific for an individual patient's tumor (ie, customized chemotherapy). This communication illustrates the successful application of such an approach in a patient with relapsed acute lymphoblastic leukemia.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15228234

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN： 0091-7370            Impact factor:   1.256


  5 in total

1.  Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.

Authors:  Andrés E Quesada; Nghia D Nguyen; Adan Rios; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

2.  [Bortezomib and obatoclax for dual blockade of protein degradation pathways show synergistic anti-tumor effect in human acute T lymphoblastic leukemia cells].

Authors:  Dan Zhou; Lixia Dai; Xiaolian Liu; Fuchang Que; Yuyan Xu; Xin Luo; Yaolu Zhu; Shuwen Liu; Yilei Li; Le Yu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-04-30

3.  Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.

Authors:  Denise Niewerth; Gertjan J L Kaspers; Gerrit Jansen; Johan van Meerloo; Sonja Zweegman; Gaye Jenkins; James A Whitlock; Stephen P Hunger; Xiaomin Lu; Todd A Alonzo; Peter M van de Ven; Terzah M Horton; Jacqueline Cloos
Journal:  J Hematol Oncol       Date:  2016-09-06       Impact factor: 17.388

4.  Morphoproteomic-Guided Host-Directed Therapy for Tuberculosis.

Authors:  Robert E Brown; Robert L Hunter; Shen-An Hwang
Journal:  Front Immunol       Date:  2017-02-02       Impact factor: 7.561

5.  Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.

Authors:  Kazuya Takahashi; Takeshi Inukai; Toshihiko Imamura; Mio Yano; Chihiro Tomoyasu; David M Lucas; Atsushi Nemoto; Hiroki Sato; Meixian Huang; Masako Abe; Keiko Kagami; Tamao Shinohara; Atsushi Watanabe; Shinpei Somazu; Hiroko Oshiro; Koshi Akahane; Kumiko Goi; Jiro Kikuchi; Yusuke Furukawa; Hiroaki Goto; Masayoshi Minegishi; Shotaro Iwamoto; Kanji Sugita
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.